The pharmaceutical industry is experiencing a surge in demand for weight-loss drugs, particularly those known as GLP-1s, leading to shortages and a scramble by companies to boost production. A Comment article in Nature has sparked a call for discussion about the social implications of substantial weight loss through drug use, highlighting potential stigmatization of individuals taking appetite-affecting drugs. Central Texas doctors have noted both benefits and risks associated with the use of the diabetes medicine Ozempic for weight loss. Eli Lilly's drug, also used for weight loss and diabetes, has shown potential as a treatment for fatty liver disease in a midstage trial. Amgen's experimental candidate aims for quicker weight loss with less frequent dosing, and Novo Nordisk's treatments are generating significant revenue for the company. The European Medicines Agency is investigating the impact on drug availability from a deal involving Catalent and Novo Nordisk. Amidst this, new ventures like Scion Life Sciences are launching with substantial funding, specifically $310M, to support biotech startups. Doctors are prescribing weight loss injections that supercharge the Ozempic effect and may soon come in a pill form, with a call for these costly drugs to be subsidized.
Pharma's favorite thing? A GLP-1 in the portfolio. Pharma's least favorite thing? A GLP-1 in the pipeline. https://t.co/huO9ew6ePv
New and effective weight loss drugs have been a game changer for people. But, experts say those who take weight loss drugs should not neglect diet and exercise. Here's what to know. https://t.co/SL18gwfES3 https://t.co/wOgsmwVRZg
gyms, nutrition startups and drugmakers alike are all racing to stop muscle loss from weight loss drugs https://t.co/l5OOp2x0m8
Ro is pursuing compounded GLP1. Interesting timing, considering major obesity organizations put out a joint statement warning against this practice. @OMAsocial @ObesityAction @ObesitySociety https://t.co/suTBlVqCq7 https://t.co/LinxnkAjPb
I continue to voice my concern for the uncertainty around the new weight loss drugs, especially because we do not understand the long-term effects yet. Please be very cautious if you are considering using these. https://t.co/eTO3HBkKmA
The weight loss drug has a muscle loss side-effect so people are taking muscle-gain drugs ... which will also have side-effects, which they'll then have to correct? https://t.co/f1uUuvsrf2
I'm so interested in the ripple effects of the GLP1 drug revolution. Here's one I'm watching: Ozempic etc make ppl lose a lot of fat—and muscle. Muscle loss is bad. So the popularity of these drugs is stimulating the search for legal, safe muscle drugs. https://t.co/hPtXfeMYTX
Drug companies Novo Nordisk and Eli Lilly are going to extraordinary lengths to secure the plants and machinery needed to churn out their popular appetite-suppressing drugs. https://t.co/kbC87Z4p3t
Our lead drug azelaprag is featured in @nytimes in a piece about the search for combination treatments to maintain healthy body composition on GLP-1/incretin drugs. BioAge plans to initiate a Ph2 trial of azelaprag + tirzepatide for obesity in mid-2024. https://t.co/8skVCGhUak
🎙️ From @Breakingviews: Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. @TheRealLSL and @rob_cyran join @aimeedonnellan and @AnitaRamaswamy on the Viewsroom podcast to discuss the obesity drug craze and its effects https://t.co/o52ATBC2DL https://t.co/XJdoXvjy78
As drugs like Ozempic become increasingly popular for weight loss, more doctors and patients are looking for ways to counteract the muscle loss that can happen on these medications. Luxury gyms and meal delivery services are racing to meet that demand. https://t.co/ga0HQ2GpjH
People taking a popular type of drug for weight loss or to manage diabetes have a lower likelihood of being newly diagnosed with depression or anxiety, a new analysis finds. https://t.co/g791qMb2WH https://t.co/v8dro5zTqg
Breakingviews - The obesity drug craze is entering its next phase: podcast https://t.co/tstKOE0QrM https://t.co/tstKOE0QrM
The #OreoVsStatin study by @nicknorwitz highlights provocative questions about lipid metabolism and #LEM. Interesting NEW 5m vid https://t.co/Et0TJtGbRN YouTube: https://t.co/pp0kI5ZGXW
From Breakingviews - Breakingviews - The obesity drug craze is entering its next phase: podcast https://t.co/cspjiHeYyX https://t.co/cspjiHeYyX
The European Medicines Agency will investigate any risks to the availability of medicines processed at Catalent plants that will be sold to Novo Nordisk. https://t.co/tPFswE9UK2
“A couple of CEOs from, say, food companies have been calling me,” Novo CEO Lars Fruergaard Jorgensen said. He declined to name names, saying questions had centered on how the drugs work and how fast they would roll out. “They are scared about it.” https://t.co/zT29iazlac
NOVO CEO: “.. A couple of CEOs from, say, food companies have been calling me. .. They are scared about it.” @business $NVO @HammerstoneMar3 https://t.co/ur0vcHtPEF https://t.co/qVAEXKOYET
Makers of everything from snack food to knee implants are facing a potential threat from Novo Nordisk’s powerful appetite-suppressing treatments. So they’re calling the drugmaker for advice. $NOVOB https://t.co/l5xrFqsXL4 via @business
PREVIEW: The Drug Pipeline for Obesity Therapeutics https://t.co/EfWUgbIiQs https://t.co/lxmi5Px3AQ
Makers of everything from snack food to knee implants are facing a potential threat from Novo Nordisk’s powerful appetite-suppressing treatments. So they’re calling the drugmaker for advice. https://t.co/kuc0yY5nXl
Weight loss drugs linked to lower likelihood of depression and anxiety diagnoses, according to a new study. https://t.co/aHvbKyUO1y
Low body fat, regular exercise, and avoiding garbage food will do you far more good than years of annual check-ups with mainstream healthcare.
People will take drugs with unknown side effects to lose weight. They'll have MAJOR surgery with huge risks to lose fat. No one wants to just eat less and move more. You don't need to be a fitness and diet expert to not be obese. You could quite literally just eat like a normal…
EU watchdog looking into impact on drug availability from Catalent-Novo deal https://t.co/lYvzzVsyim https://t.co/ar5RI0uRJd
Venture firm Scion Life Sciences launches with $310M to back new #biotechs https://t.co/jKyTQYjncU by @gwendolynawu
"Until recently, the very notion of prescribing any form of weight loss whatsoever to an elderly patient—i.e., someone 65 or older—was considered suspect, even dangerous … among the people who were on the weight-loss program for more than a decade, their risk of fracture to the…
Amgen’s dog in the obesity drug race, MariTide, stimulates weight loss in animals and people without major side effects, new data show. And, unlike its competitors, it may only need to be taken once a month and perhaps not for life. $AMGN https://t.co/hIvgdLVqMS
The need-to-know in biotech this morning: The arrival of Scion Life Sciences, GLP-1 drug panic and the weight of expectations on Eli Lilly. https://t.co/MIqZZf2gGx
The need-to-know in biotech this morning: —The arrival of Scion Life Sciences —GLP-1 drug panic —The weight of expectations on Eli Lilly https://t.co/a9UJ02LFiY
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about worries over a Novo deal, a PBM bill & More news.. https://t.co/iwbw0nO0zP #pharma #obesity #weightloss #antitrust #patents #cancer #FDA #COVID19 #PBM #HIV #AIDS $NVO $CTLT $LLY $GILD $GSK
Eli Lilly is worried a deal to expand production of Novo Nordisk's weight-loss drug might hinder its ability to get drugs to customers. https://t.co/hM53DPnPi3
This interview is a tour de force. Covering Ozempic, obesity, diabetes, drugs, corruption, why pharma funds media ads & more... @calleymeans https://t.co/TxHhSwEStY
Weight-loss programs for seniors were once considered dangerous and still remain controversial. So what happens when millions of older adults try out drugs such as Wegovy, Zepbound, and Ozempic? @danengber explores: https://t.co/cNn4lbvrls
Weight-loss programs for seniors were once considered dangerous and still remain controversial. So what happens when millions of older adults try out drugs such as Wegovy, Zepbound, and Ozempic? @danenger explores: https://t.co/Bawfqbqch9
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences. https://t.co/7JqBQDKqWx
A new biotech VC firm is eschewing some of what its founders call the "artifacts" of venture investing, in the hopes of building the next independent, scalable biotech like Vertex or Regeneron. https://t.co/2WNKgTHLJS Scion Life Sciences
Industry veterans launch new biotech VC fund with $310M https://t.co/22MbL8RmVh
Venture firm Scion Life Sciences launches with $310M to back new #biotechs https://t.co/57ivumAtjg by @gwendolynawu #startups
Doctors have begun prescribing the next phase of weight loss injections which supercharge the Ozempic effect and may soon come in a pill form. But they want the costly drugs to be subsidised for everyone to tackle obesity and ward off diabetes. https://t.co/mUHxcVEqnZ #7NEWS https://t.co/0HhRPSxMUJ
Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. https://t.co/pYhrdRBBYX
Shortages of weight-loss drugs are driving pharmaceutical companies to scramble to shore up supplies. Booming demand for anti-obesity drugs, known as GLP-1s, has led to a windfall of revenue for pharma giants like Novo Nordisk and Eli Lilly. https://t.co/7Zaw7jXYgx
Amgen's most advanced experimental candidate activates GLP-1 while blocking GIP. It says its goal is quicker weight loss, less frequent dosing and possibly better weight maintenance. https://t.co/6qoAFmnSS6
Many people have turned to the diabetes medicine Ozempic as a weight loss treatment, but a Central Texas doctor says there are both benefits and risks involved. https://t.co/bcYGv33chr
Our founder @calleymeans sheds light on the obesity epidemic in America and the negative effects of Ozempic. This is a must watch!⬇️ https://t.co/bkiw8c29a9
Drug companies scramble to boost production of weight-loss drugs https://t.co/CFi4BZ1EHc @NathanBomey
Ideas of diet and exercise as the ‘best’ way to lose weight could stigmatize people taking drugs that affect appetite. A Comment article in @Nature call for a discussion about the social downsides of achieving substantial weight loss through drug use. https://t.co/PbhOqTwzu9